Table 5.

Univariate analysis of CTC status and overall and progression-free survival according to disease setting

	Overall survival (months)		Progression-free survival (months)
	CTC-positive vs. CTC-negative	p value	CTC-positive vs. CTC-negative	p value
Entire cohort (n = 43)	Mean 12.3 [95% CI 4.4—20.1] vs. 24.6 [19.7–29.4] Median: 3.1 [0.0–12.0] vs. NR	0.006	Mean 10.6 [3.8–17.4] vs. 22.1 [17.2–26.9] Median: 3.1 [0.0–12.0] vs. 23.1 [13.1–33.1]	0.005
Primary cancer (n = 23)	Mean 17.4 [1.7–33.1] vs. 29.0 [24.3–33.7] Median 1.9 vs. NR	0.192	Mean 14.3 [1.0–27.7] vs. 26.9 [22.2–31.6] Median 2.0 [0.0–21.9] vs. NR	0.085
Recurrent/progressive disease (n = 20)	Mean 6.8 [2.9–10.7] vs. 13.0 [6.3–19.7] Median 3.1 [1.8–4.5] vs. 11.1 [2.6–19.6]	0.169	Mean 6.8 [2.9–10.7] vs. 11.7 [5.5–17.9] Median 3.1 [1.8–4.5] vs. 4.9 [0.0–14.0]	0.251

CI confidence interval, NR not reached